SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 99,287.65 |
| Enterprise Value ($M) | 138,214.65 |
| Book Value ($M) | 17,448.00 |
| Book Value / Share | 8.54 |
| Price / Book | 5.69 |
| NCAV ($M) | -44,196.00 |
| NCAV / Share | -21.72 |
| Price / NCAV | -2.25 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | 0.08 |
| Return on Assets (ROA) | 0.05 |
| Return on Equity (ROE) | 0.33 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 1.17 |
| Current Ratio | 1.28 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 30,783.00 |
| Assets | 92,427.00 |
| Liabilities | 74,979.00 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 48,300.00 |
| Operating Income | 9,705.00 |
| Net Income | -8,948.00 |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 15,190.00 |
| Cash from Investing | -21,352.00 |
| Cash from Financing | 5,127.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G | Jpmorgan Chase & Co | 5.10 | ||
| 13G/A | BlackRock, Inc. | 7.10 | -14.59 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 3,431,998 | 11,069,967 | 31.00 | |
| 2,748,331 | 11,770,883 | 23.35 | |
| 1,661,836 | 7,805,161 | 21.29 | |
| 1,394,851 | 10,084,103 | 13.83 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| ANVS – Annovis Bio, Inc. | BHC – Bausch Health Companies Inc. |
| BHVN – Biohaven Ltd. | EBS – Emergent BioSolutions Inc. |
| ELAN – Elanco Animal Health Incorporated |